Novartis Sells Swiss Manufacturing Plant to Lonza
Novartis Sells Swiss Manufacturing Plant to Lonza
GALWAY, IRELAND--January XX, 2019--Written by Martin Lynch, European News Editor for Industrial Info (Galway, Ireland)--Swiss pharmaceutical company Novartis International AG (NYSE:NVS) (Basel, Switzerland) has offloaded its sterile drug product fill and finish facility in Stein, Switzerland, to Lonza Group (Basel, Switzerland).
Within this article: Details sale of Swiss plant, activities at plant, future uses, Novartis' global changes to manufacturing and product refocusing
Subscribe Now!(All Fields Required)
Related Articles
Articles related to this company
- Novartis To Make Pfizer/BioNTech COVID-19 Vaccine in Slovenia
- Lonza Building New Swiss Plant, Expands Moderna COVID-19 Manufacturing Deal
- Novartis Opens Cell and Gene Therapy Plant in Switzerland
- Novartis Completes Spinoff of Alcon Eye Care Business
- Novartis Axing 2,550 Jobs in Switzerland and the U.K.